Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Medarex Antibody Collaboration Includes Cross-Licensing Of Melanoma Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Medarex expects cross-licensing anti-CTLA-4 products will enhance opportunities for future products by clearing up potential intellectual property issues. Pfizer will make up-front payments totaling $110 mil. to secure 50 antibody products over 10 years.

You may also be interested in...



Medarex To Start Pivotal Trial Of MDX-010/Cancer Vaccine Combo For Melanoma

The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Sepracor Lunesta Ads Are Top At Brand Recognition, IAG Research Finds

Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel